Phase 3 Orforglipron Trial in Patients on Insulin Glargine Completes

A Phase 3 clinical trial involving orforglipron (LY3502970) has reached completed status as of October 1, 2026. The study, registered as NCT06109311, examined participants with type 2 diabetes who had inadequate glycemic control while on insulin glargine. Participants in the trial were treated with or without metformin and/or an SGLT-2 inhibitor in addition to insulin glargine. The trial title identifies it as "A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor." The listed status for this study is COMPLETED and the phase is Phase 3. This update reflects the trial's status only, as recorded in its registry entry. No results or outcome data are included in this update. Insulin glargine remains an approved medication and was used as a background therapy in this study population. Readers interested in further detail on this trial can consult the registry entry directly for additional protocol information. For more background on insulin glargine itself, see the compound overview linked with this brief.